Arthur He
Stock Analyst at HC Wainwright & Co.
(4.42)
# 328
Out of 5,090 analysts
45
Total ratings
52.08%
Success rate
25.48%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Arthur He
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VERA Vera Therapeutics | Maintains: Buy | $85 → $90 | $42.61 | +111.22% | 3 | Nov 10, 2025 | |
| ADAG Adagene | Maintains: Buy | $8 → $7 | $1.97 | +255.69% | 11 | Aug 15, 2025 | |
| AUPH Aurinia Pharmaceuticals | Assumes: Buy | $17 | $15.33 | +10.89% | 1 | Jul 30, 2025 | |
| NKTR Nektar Therapeutics | Maintains: Buy | $6.5 → $120 | $57.50 | +108.71% | 4 | Jun 24, 2025 | |
| SLDB Solid Biosciences | Reiterates: Buy | $20 | $5.93 | +237.55% | 10 | Jun 17, 2025 | |
| PRME Prime Medicine | Downgrades: Neutral | n/a | $3.85 | - | 8 | May 20, 2025 | |
| BCAB BioAtla | Reiterates: Neutral | n/a | $0.85 | - | 8 | Mar 31, 2025 |
Vera Therapeutics
Nov 10, 2025
Maintains: Buy
Price Target: $85 → $90
Current: $42.61
Upside: +111.22%
Adagene
Aug 15, 2025
Maintains: Buy
Price Target: $8 → $7
Current: $1.97
Upside: +255.69%
Aurinia Pharmaceuticals
Jul 30, 2025
Assumes: Buy
Price Target: $17
Current: $15.33
Upside: +10.89%
Nektar Therapeutics
Jun 24, 2025
Maintains: Buy
Price Target: $6.5 → $120
Current: $57.50
Upside: +108.71%
Solid Biosciences
Jun 17, 2025
Reiterates: Buy
Price Target: $20
Current: $5.93
Upside: +237.55%
Prime Medicine
May 20, 2025
Downgrades: Neutral
Price Target: n/a
Current: $3.85
Upside: -
BioAtla
Mar 31, 2025
Reiterates: Neutral
Price Target: n/a
Current: $0.85
Upside: -